Phaseline

Targets › PBPA

PBPA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jan 2027.

Open in Phaseline: the race on PBPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Cephalexin
Bacterial penicillin-binding protein inhibitor
PBPAPhase 2EczemaJan 2027

Conditions

Eczema (1)

Modalities

small molecule (1)

Companies

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.